 Interferon-alpha
"Interferon-alpha" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells. In addition to antiviral activity, it activates NATURAL KILLER CELLS and B-LYMPHOCYTES, and down-regulates VASCULAR ENDOTHELIAL GROWTH FACTOR expression through PI-3 KINASE and MAPK KINASES signaling pathways.
| Descriptor ID |
D016898
|
| MeSH Number(s) |
D12.644.276.374.440.890.250 D12.776.467.374.440.890.250 D23.529.374.440.890.250
|
| Concept/Terms |
Interferon-alpha- Interferon-alpha
- Interferon alpha
- alpha-Interferon
- alpha Interferon
- Interferon, Lymphoblastoid
- Lymphoblastoid Interferon
- Interferon, Lymphoblast
- Lymphoblast Interferon
- Interferon Alfa
- Interferon, alpha
- Interferon, Leukocyte
- Leukocyte Interferon
Interferon alpha-17- Interferon alpha-17
- Interferon alpha 17
- Interferon alpha-T
- Interferon alpha T
- LeIF I
- Interferon alpha-88
- Interferon alpha 88
Interferon alpha-7- Interferon alpha-7
- Interferon alpha 7
- LeIF J
- Interferon alpha-J
- Interferon alpha J
Interferon alpha-5- Interferon alpha-5
- Interferon alpha 5
- Interferon alpha5
- IFN-alpha5
- IFN alpha5
Interferon alpha-2- Interferon alpha-2
- Interferon alpha 2
- Interferon-alpha 2
- Interferon alpha-A
- Interferon alpha A
- LeIF A
- IFN-alpha 2
- IFN-alpha-2
|
Below are MeSH descriptors whose meaning is more general than "Interferon-alpha".
Below are MeSH descriptors whose meaning is more specific than "Interferon-alpha".
This graph shows the total number of publications written about "Interferon-alpha" by people in this website by year, and whether "Interferon-alpha" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 1 | 3 | | 1997 | 2 | 0 | 2 | | 1998 | 1 | 1 | 2 | | 1999 | 2 | 1 | 3 | | 2002 | 1 | 2 | 3 | | 2003 | 2 | 0 | 2 | | 2004 | 3 | 0 | 3 | | 2005 | 1 | 2 | 3 | | 2006 | 3 | 3 | 6 | | 2007 | 2 | 3 | 5 | | 2008 | 3 | 0 | 3 | | 2009 | 2 | 3 | 5 | | 2010 | 10 | 4 | 14 | | 2011 | 2 | 2 | 4 | | 2012 | 2 | 4 | 6 | | 2013 | 3 | 3 | 6 | | 2014 | 6 | 5 | 11 | | 2015 | 2 | 5 | 7 | | 2016 | 2 | 2 | 4 | | 2017 | 1 | 1 | 2 | | 2018 | 3 | 1 | 4 | | 2019 | 2 | 3 | 5 | | 2020 | 1 | 2 | 3 | | 2021 | 1 | 0 | 1 | | 2022 | 0 | 2 | 2 | | 2023 | 0 | 1 | 1 | | 2024 | 1 | 0 | 1 | | 2025 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Interferon-alpha" by people in Profiles.
-
Hayashi Y, Hatano M, Kaneko S, Shimbo A, Irabu H, Mori M, Shimizu M. Macrophage activation syndrome associated with neonatal lupus erythematosus. Lupus. 2025 Aug; 34(9):978-981.
-
Fukuda R, Fujiwara Y, Maeda H, Pan C, Minayoshi Y, Yano H, Mizuta Y, Takano M, Yamada R, Saito Y, Hirata K, Imoto S, Yamasaki K, Oniki K, Saruwatari J, Otagiri M, Watanabe H, Komohara Y, Maruyama T. Lymph node macrophage-targeted interferon alpha boosts anticancer immune responses by regulating CD169-positive phenotype of macrophages. Mol Cancer. 2025 May 03; 24(1):132.
-
Kaneko S, Shimbo A, Irabu H, Hatano M, Takasawa K, Kamiya T, Akamine K, Tanaka T, Minato T, Ono M, Yokoyama K, Arisaka A, Yasumi T, Ueno K, Fujita S, Tanaka Y, Hayashi D, Nishikawa H, Fujita Y, Yuza Y, Mori M, Morio T, Shimizu M. Pathogenic role and diagnostic utility of interferon-a in histiocytic necrotizing lymphadenitis. Clin Immunol. 2024 Sep; 266:110324.
-
Zanin N, Viaris de Lesegno C, Podkalicka J, Meyer T, Gonzalez Troncoso P, Bun P, Danglot L, Chmiest D, Urbé S, Piehler J, Blouin CM, Lamaze C. STAM and Hrs interact sequentially with IFN-a Receptor to control spatiotemporal JAK-STAT endosomal activation. Nat Cell Biol. 2023 03; 25(3):425-438.
-
Wotman KL, Chow L, Martabano B, Pezzanite LM, Dow S. Novel ocular immunotherapy induces tumor regression in an equine model of ocular surface squamous neoplasia. Cancer Immunol Immunother. 2023 May; 72(5):1185-1198.
-
Saleiro D, Wen JQ, Kosciuczuk EM, Eckerdt F, Beauchamp EM, Oku CV, Blyth GT, Fischietti M, Ilut L, Colamonici M, Palivos W, Atsaves PA, Tan D, Kocherginsky M, Weinberg RS, Fish EN, Crispino JD, Hoffman R, Platanias LC. Discovery of a signaling feedback circuit that defines interferon responses in myeloproliferative neoplasms. Nat Commun. 2022 04 01; 13(1):1750.
-
Ptacek J, Hawtin RE, Sun D, Louie B, Evensen E, Mittleman BB, Cesano A, Cavet G, Bingham CO, Cofield SS, Curtis JR, Danila MI, Raman C, Furie RA, Genovese MC, Robinson WH, Levesque MC, Moreland LW, Nigrovic PA, Shadick NA, O'Dell JR, Thiele GM, Clair EWS, Striebich CC, Hale MB, Khalili H, Batliwalla F, Aranow C, Mackay M, Diamond B, Nolan GP, Gregersen PK, Bridges SL. Diminished cytokine-induced Jak/STAT signaling is associated with rheumatoid arthritis and disease activity. PLoS One. 2021; 16(1):e0244187.
-
Tuttle KD, Waugh KA, Araya P, Minter R, Orlicky DJ, Ludwig M, Andrysik Z, Burchill MA, Tamburini BAJ, Sempeck C, Smith K, Granrath R, Tracy D, Baxter J, Espinosa JM, Sullivan KD. JAK1 Inhibition Blocks Lethal Immune Hypersensitivity in a Mouse Model of Down Syndrome. Cell Rep. 2020 11 17; 33(7):108407.
-
Guo K, Shen G, Kibbie J, Gonzalez T, Dillon SM, Smith HA, Cooper EH, Lavender K, Hasenkrug KJ, Sutter K, Dittmer U, Kroehl M, Kechris K, Wilson CC, Santiago ML. Qualitative Differences Between the IFNa subtypes and IFNß Influence Chronic Mucosal HIV-1 Pathogenesis. PLoS Pathog. 2020 10; 16(10):e1008986.
-
Alsyouf M, Pierorazio P, Groegler J, Hu B. Chemoablation in Urothelial Carcinoma: A Systematic Review and Future Perspectives. Urology. 2020 10; 144:28-37.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|